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Kinase suppressor of Ras 2 (KSR2) is an intracellular
scaffolding protein involved in multiple signaling
pathways. Targeted deletion of Ksr2 leads to obesity
in mice, suggesting a role in energy homeostasis. We
explored the role of KSR2 in humans by sequencing
2,101 individuals with severe early-onset obesity and
1,536 controls. We identified multiple rare variants in
KSR2 that disrupt signaling through the Raf-MEK-
ERK pathway and impair cellular fatty acid oxidation
and glucose oxidation in transfected cells; effects
that can be ameliorated by the commonly pre-
scribed antidiabetic drug, metformin. Mutation car-
riers exhibit hyperphagia in childhood, low heart
rate, reduced basal metabolic rate and severe insulin
resistance. These data establish KSR2 as an impor-
tant regulator of energy intake, energy expenditure,
and substrate utilization in humans. Modulation of
KSR2-mediated effects may represent a novel thera-
peutic strategy for obesity and type 2 diabetes.INTRODUCTION
Cells sense the nutritional status of the organism, monitor intra-
cellular energy stores, and transmit this information to signal
transduction pathways that drive cellular proliferation and differ-
entiation. The Ras-Raf-MEK signaling pathway is fundamental tocellular metabolism and growth in humans; inherited mutations
involving this pathway cause disorders of early growth anddevel-
opment (Tartaglia and Gelb, 2010), whereas sporadic activating
mutations have been identified in at least 30% of human cancers
(Lawrence et al., 2008). Circulating hormones and growth factors
activate cell surface receptor tyrosine kinases, stimulating the
GTP loading of Ras, which permits recruitment of the cytosolic
Ser/Thr protein kinase Raf to the plasma membrane, where it is
activated (McKay and Morrison, 2007). Membrane-bound Raf
phosphorylates and activates the dual-specificity kinase MEK,
which in turn phosphorylates ERK, which then translocates to
the nucleus where it regulates gene expression.
The kinase suppressors of Ras proteins (KSR1andKSR2) were
originally identified from genetic screens in Drosophila and
C. elegans (Kornfeld et al., 1995; Sundaram andHan, 1995; Ther-
rien et al., 1995) and found to act as positive regulators of theRas-
Raf-MEK signaling pathway by acting as scaffolding proteins
(Nguyen et al., 2002). Both KSR1 and 2 bind to Raf, MEK, and
ERK, facilitating their phosphorylation and activation (Denouel-
Galy et al., 1998; Dougherty et al., 2009; Roy et al., 2002; Therrien
et al., 1996). In addition, KSR proteins translocate to the plasma
membrane in response to growth factor stimulation (Mu¨ller
et al., 2001), thereby regulating thespatial and temporal dynamics
of Ras-Raf-MEK signaling aswell as increasing the efficiency and
specificity of this pathway. The recently solved KSR2-MEK1
structure has revealed howKSR2 regulatesMEK activation by in-
teracting with B-Raf (Brennan et al., 2011). Proteomic studies
have also shown that KSR2 interacts with multiple proteins in-
cluding AMP-activated protein kinase (AMPK) (Costanzo-Garvey
et al., 2009; Liu et al., 2009), a phylogenetically conservedSer/ThrCell 155, 765–777, November 7, 2013 ª2013 The Authors 765
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Figure 1. Identification of Multiple KSR2 Mutations in Severely Obese Individuals and Controls
(A) Mutations in KSR2 identified in individuals with severe early-onset obesity and in controls (shown in gray). Mutations identified by whole-exome sequencing
are marked with an asterisk; all others were identified by Sanger sequencing. Mutation numbering is based on Ensembl transcript ID ENST00000339824 and
Protein ID ENSP00000339952; Het = heterozygous and Hom = homozygous. As BMI (kg/m2) varies with age and gender, the BMI and BMI SD scores (sds) are
noted. The potential functional consequences of each mutation were assessed using Polyphen2 and SIFT.
(legend continued on next page)
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protein kinase that acts as a fuel sensor, monitoring cellular en-
ergystatus ineukaryotes.Underconditionsof nutrientdeprivation
and cellular stress, intracellular ATP levels fall and levels of AMP
rise, promoting AMPK activation that in turn promotes catabolic
processes and inhibits anabolic pathways (Hardie et al., 2012).
The interaction between KSR2 and AMPK has been suggested
to underpin some of the abnormalities of energy homeostasis
and metabolism seen in Ksr2/ mice, which include obesity,
high insulin levels, and impaired glucose tolerance (Brommage
et al., 2008; Costanzo-Garvey et al., 2009; Revelli et al., 2011).
Ksr2+/ mice also develop obesity when fed on a high-fat diet,
indicating that the physiological effects of Ksr2 disruption on
energy balance are dosage dependent (Revelli et al., 2011).
In this study, we found a large number of variants in KSR2 in
individuals with severe early-onset obesity. Many of the variants
studied impaired signaling through the Raf-MEK-ERK pathway.
While some of the variants reduced the interaction between
KSR2 and AMPK, when compared to wild-type KSR2, almost
all KSR2 variants impaired glucose oxidation and palmitate-
stimulated fatty acid oxidation (FAO) in transfected cells. These
observations indicate that multiple molecular and cellular mech-
anisms underlie the phenotype associated with disruption of
KSR2 in humans, which is characterized by hyperphagia, low
basal metabolic rate, obesity, and severe insulin resistance.
RESULTS
Identification of KSR2 Variants in Obese Individuals
To comprehensively address whether genetic variants in KSR2
contribute to obesity, we sequenced the coding region and
intron/exon boundaries of KSR2 in 1,770 individuals of mixed
European descent with severe, early-onset obesity (mean body
mass index [BMI] standard deviation score 3.5; age of onset
<10 years) who were recruited to the Genetics of Obesity Study
(GOOS) (Farooqi et al., 2003). We also reviewed KSR2 sequence
data obtained from whole-exome sequencing of 331 additional
unrelated individuals from the GOOS cohort. We compared the
data on individuals with severe obesity to that obtained from
sequencing 1,536 control individuals from a large UK popula-
tion-based study, the ELY study (Williams et al., 1995).
A total of 2.1% of GOOS versus 1.0% of controls had a rare
(minor allele frequency (MAF) < 0.5%) frameshift, nonsense or
missense variant in KSR2 (Figure 1A and Table S1 available on-
line).We identified 27 different rare variants in 45/2,101 unrelated
severely obese individuals screened compared to 7 different rare
variants in 16/1,536 controls (Figure 1A and Table S1; Fisher’s
exact test using different MAF thresholds adjusted by permuta-
tion, p = 0.0025). A combined analysis including a replication
sample of 238 cases and 1,117 controls (total 2,339 cases and
2,653 controls), resulted in a permutation adjusted Fisher’s exact
test p value = 0.0063 (Table S2).
Most variants were found in heterozygous form, although one
severely obese individual was homozygous for two KSR2 vari-(B) Schematic representation of full-length KSR2 (Q6VAB6), indicating the loca
obesity and those found in controls (shown in gray). Domains conserved in KSR1
green; the kinase domain is indicated in red. The mutations found in severely obe
red. See also Tables S1 and S2 and Figure S1.ants (R253W and D323E). Twenty-three of the variants identified
were found only in severely obese individuals, and many were
predicted to be functionally deleterious and altered highly
conserved residues (Figure S1), suggesting they may have func-
tional consequences. Five nonsynonymous variants were found
in obese cases but also in controls in this study (Figure 1A and
Table S1). Three variants were found only in controls, all of
whom were overweight/obese (Figure 1A). We compared the
frequency of rare variants in severely obese cases and normal
weight controls only (n = 1,353). Using a Fisher’s exact test
and permutation to adjust for using different MAF thresholds
for rare variants, we found that there was significant enrichment
for rare variants in KSR2 in severely obese cases (n = 45/2,101)
versus normal weight controls (n = 14/1,353); p = 0.0021.
We sequenced KSR2 in available family members (n = 44) of
severely obese probands. Eighteen of the 19 variant carriers
were overweight or obese (Table S1), although variants did not
consistently cosegregate with obesity in families in a classical
Mendelian manner. These findings suggest that KSR2 variants
predispose to obesity against a background of other genetic
and environmental factors.
KSR2 Mutations Disrupt Signaling through the
Ras-Raf-MEK-ERK Pathway
We next performed a series of studies to explore the molecular
mechanisms by which mutations found in severely obese indi-
viduals might disrupt KSR2 function. We investigated the impact
of the mutations on KSR20s ability to facilitate signaling through
the Raf-MEK-ERK pathway. Due to the large number of variants
identified (Figure 1B), we focused on variants that disrupt (frame-
shift/nonsense) or are likely to disrupt (missense mutations in or
very close to) the highly conserved kinase domain. There was
significant enrichment for variants in this domain in severe
obesity (17/2,101) compared to nonobese controls (3/1,353)
using Fisher’s exact test (p = 0.036).
AshumanKSR2hasnotpreviouslybeen functionally character-
ized, we studied two isoforms, KSR2_950 and KSR2_921, which
differ in their first 29 amino acids. Both KSR2 isoforms displayed
a similar diffuse cytoplasmic distribution, with localization also
detected at the plasma membrane (data not shown). KSR2_921
was expressed at a lower level and had a reduced ability to bind
B-Raf and facilitate MEK and ERK phosphorylation. All subse-
quent experiments were therefore performed with KSR2_950.
Using confocal microscopy, we investigated the intracellular
localization of WT and mutant KSR2 expressed in Cos7 cells
and its colocalization with endogenous B-Raf, MEK, or ERK.
None of the mutations affected the intracellular localization of
KSR2 (Figure S2). WT KSR2 colocalized with B-Raf, MEK, and
ERK in the cytoplasm and at the plasma membrane and this
was unaffected by the mutations (Figures 2A and S2).
To determine whether KSR2 mutations affect Ras-Raf-MEK-
ERK signaling, HEK293 cells were transfected with Flag-tagged
WT and mutant forms of KSR2 and stimulated with EGF. Usingtion of each of the mutations identified in individuals with severe early-onset
are indicated in blue (CA1-4) and the domain found only in KSR2 is shown in
se individuals that were subjected to functional characterization are shown in
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Figure 2. Obesity-Associated KSR2 Mutations Disrupt Raf/MEK/ERK Signaling
(A) Confocal microscopy of EGF-stimulated Cos7 cells showing the colocalization of transiently expressed KSR2 WT and the frameshift mutation, L822Pfsx26
(green), with endogenous B-Raf, MEK, and ERK (red) in the cytoplasm and plasma membrane (inset). Scale bars, 10 mm.
(B) HEK293 cells transfected with the indicated KSR2 constructs were serum starved for 16 hrs prior to stimulation with 50 ng/ml EGF for 10 min. Lysates were
subjected to immunoprecipitation with Flag-agarose and immunoblotted with the indicated antibodies.
(C) Top: Flow cytometry density plots showing the effect of KSR overexpression on ERK phosphorylation. Bottom: Flow cytometry histograms gated on
transfected cells, comparing the effect on ERK phosphorylation of overexpressing different KSR2mutants (black) versusWTKSR2 (Red). A background control is
shown in blue. See also Figure S2.coimmunoprecipitation, we found that WT KSR2 was consti-
tutively bound to MEK, consistent with previous reports
(Denouel-Galy et al., 1998; Dougherty et al., 2009; Mu¨ller et al.,
2000; Yu et al., 1998) and, upon EGF stimulation, interacted
with ERK and B-Raf (Figure 2B). In addition, phosphorylation of768 Cell 155, 765–777, November 7, 2013 ª2013 The Authorsthe KSR2-associated MEK and ERK could be detected. In
contrast, two mutations that result in truncated versions of
KSR2 that lack the kinase domain, V511Cfsx29 and Y569X,
were unable to interact with MEK and ERK and displayed a
significantly reduced ability to bind B-Raf. A similar result was
also seenwith two additional frameshift mutants, suggesting that
all four mutations result in a nonfunctional form of KSR2 (Fig-
ure 2B). The remaining missense mutations in or near the kinase
domain expressed at a similar level to WT KSR2 and retained
their ability to interact with MEK. However, the phosphorylation
of associated MEK was reduced with the P662L, R684C,
G816D, and R818Q mutants, while that of ERK was reduced
with the P662L, R684C, and R818Q mutants. In addition the
P662L, R684C, and R818Q mutants reduced the ability of
KSR2 to interact with B-Raf (Figure 2B).
While studying the colocalization of KSR2 with components of
the MAPK signaling pathway, we noticed that overexpression of
KSR2 in Cos7 cells led to reduced levels of phosphorylated ERK.
This observation is consistent with previous studies on KSR1,
which showed that overexpression of KSR1 results in attenuated
ERK activation (Joneson et al., 1998). We used flow cytometry to
measure the effect of overexpressing wild-type and mutant
KSR2 on ERK phosphorylation. Cells transfected with WT
KSR2 were found to have a substantial reduction in ERK phos-
phorylation compared to a control protein. In contrast, the
V511Cfsx29, Y569X, F807Qfsx41, and L822Pfsx26 mutants
did not reduce ERK activation, providing further evidence that
they are nonfunctional (Figure 2C).
Mutations in KSR2 Disrupt Interactions between the
Kinase Domain, B-Raf, and MEK
We modeled the mutations using the structure of the KSR2
kinase domain in complex with MEK (Brennan et al., 2011) (Fig-
ures 3A and 3B). Of the three frameshift mutants, V511Cfsx29
results in a truncated protein that not only lacks the ERK-binding
domain but also the entire kinase domain leading to a
completely nonfunctional KSR2 molecule (Figure S3). Similarly,
the Y569X nonsense mutation also removes the kinase domain.
F807fsx41 and L822Pfsx26 fall within the activation segment of
the KSR2 kinase domain, resulting in the loss of the APE motif,
a conserved feature of all protein kinases that is involved in sub-
strate binding, and also the remainder of the kinase domain,
including the aG helix (Figure S3). This would be expected to
completely destabilize the interaction of KSR2 and MEK and
explains our finding that none of the frameshift mutants, nor
the nonsense mutant, are able to interact with MEK (Figure 2B).
The P662L, E667V, and R684C mutations lie within the N-lobe
of the kinase domain, in a region involved in binding B-Raf (Fig-
ure 3A). P662 is directly involved in the interaction with B-Raf
(Figure 3C), and R684 forms a long electrostatic contact to
Glu664 of B-Raf (Figure 3D), explaining how mutation of these
residues leads to reduced B-Raf binding. The remaining point
mutations are located in the C-lobe of the catalytic domain.
I801 lies close to the DFG motif within the activation segment
(Figure 3E); G816 and R818 also lie in the activation segment,
although this region (808–819) is disordered in the KSR2 kinase
domain structure. Additionally, R823 and D843 lie close to the
KSR2-MEK interface (Figures 3F and 3G), and thus mutations
of these residues may disrupt KSR2-MEK interactions. S904 is
not directly involved in binding to MEK and B-Raf (Figure 3H);
however, a Leu substitution at this position would cause a steric
clash with Leu894 and likely destabilize the C-lobe of the KSR2
kinase domain. R936L is C-terminal to the ordered region ofthe kinase domain and so was not studied. Cumulatively, these
findings indicate that the nonsense, frameshift, and some of
the point mutations disrupt key interactions between KSR2
and B-Raf and MEK.
Human Phenotype Associated with Loss-of-Function
KSR2 Mutations
We next sought to determine the phenotype associated with
loss-of-function mutations in KSR2 in humans. Eighteen pro-
bands and family members harboring KSR2 variants (mean
BMI ± SEM = 35.4 ± 7.5 kg/m2) consented to take part in clinical
studies (Table S1). We compared their data to 26 equally obese
volunteers recruited from the local community (mean BMI
36.4 ± 7.0 kg/m2) in whom variants in KSR2 were excluded by
sequencing.
Final height of male (176.1 ± 3.2 cm) and female (165.8 ±
1.2 cm) KSR2 mutation carriers was not significantly different
from obese controls (176.3 ± 1.9 cm and 165.2 ± 1.8 cm, respec-
tively), suggesting that heterozygous loss-of-function KSR2
mutations do not adversely affect linear growth. We measured
body composition by dual energy X-ray absorptiometry (DEXA).
The mean percentage body fat of KSR2 mutation carriers
(47.0% ± 2.0%) was similar to that of obese controls (45.8% ±
1.2%). There was a history of increased food-seeking behavior
in childhood and energy intake at an 18MJ ad libitum test meal
given to children after an overnight fast was significantly greater
than that of 14 normal weight children (Figure 4A). However, hy-
perphagia was reported as being less prominent with age and
in adult KSR2 mutation carriers, measured ad libitum energy
intake did not differ significantly from obese controls (Figure 4B).
Basal metabolic rate (BMR) measured by indirect calorimetry
correlates very closely with energy expenditure predicted on
the basis of age, gender, and body composition (Cunningham,
1991) in normal weight and obese healthy subjects and in individ-
uals with genetic forms of obesity affecting leptin-melanocortin
signaling (Farooqi et al., 2007; Greenfield et al., 2009). We
measured BMR in KSR2mutation carriers in thermoneutral con-
ditions after a 10 hr supervised fast. Measured BMR was less
than predicted BMR in children with KSR2 mutations (8.0 ±
0.7 MJ/day versus 8.3 ± 0.7 MJ/day), although this was not sta-
tistically significant. However, measured BMR was significantly
reduced compared to predicted BMR in adult mutation carriers
(Figure 4C). In addition, the respiratory quotient (RQ; ratio of
carbohydrate to fat oxidation) was increased in KSR2 mutation
carriers compared with obese controls (Figure 4D).
We measured heart rate and heart rate variability using a
portable digital accelerometer, a noninvasive device for quanti-
fying autonomic nervous system activation. Heart rate was
measured continuously for 24 hr in adults only, as heart rate
cannot readily be compared across children of different ages.
Sleeping heart rate was significantly lower in KSR2 mutation
carriers compared to obese controls (Figure 4E; p = 0.01). The
increase in heart rate with waking was comparable in both
groups (Figure 4E). There were no differences in the root mean
square of successive differences (RMSSD), low-frequency (LF)
power or high-frequency (HF) power components between the
two groups (data not shown), suggesting that autonomic tone
is preserved in KSR2mutation carriers. Twenty-four hour urinaryCell 155, 765–777, November 7, 2013 ª2013 The Authors 769
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Figure 3. Structural Modeling of Mutations within the Kinase Domain of KSR2
(A and B) Structure of the MEK1-KSR2-BRAF ternary complex (Brennan et al., 2011) indicating the location of all the mutations studied.
(C–H) Local environment and packing interactions of specific amino acid substitutions in KSR2. Disease-associated residues are shown in pink. See also
Figure S3.norepinephrine, epinephrine, and dopamine excretion, thyroid-
stimulating hormone, and free thyroxine concentrations were in
the normal range (Table S3). There was no difference in temper-
ature between KSR2 mutation carriers and obese controls
(36.5 ± 0.09C versus 36.4 ± 0.09C, respectively).
TwoKSR2mutation carrierswere excludedapriori fromstudies
due toadiagnosis of type 2diabetes. Fastingplasma insulin levels
were significantly increased in KSR2mutation carriers compared
to obese controls (Figure 4F) as were C-peptide levels (1,922 ±
120 versus 1,015 ± 77 pmol/l; p < 0.0001), consistent with
increased insulin secretion. In addition, KSR2 mutation carriers
exhibited an increased insulin response to a 75 g oral glucose
load (Figure4F).While therewasnosignificantdifference in fasting
glucose levels between the groups, KSR2 mutation carriers770 Cell 155, 765–777, November 7, 2013 ª2013 The Authorsexhibited impairedglucose tolerance (Figure4G).Allmutationcar-
riers had clinical evidence of acanthosis nigricans; hyperpigmen-
tation of axillary and flexural skin, which is a recognizedmarker of
severe insulin resistance. Mean systolic and diastolic blood pres-
sures, fasting cholesterol, triglycerides, and adiponectin levels
were comparable to those seen in obese controls (Table S3).
Increased Energy Intake and Decreased Energy
Expenditure in Ksr2 Null Mice
To further investigate how energy homeostasis is perturbed
when KSR2 is disrupted, we performed additional studies in
Ksr2/ mice. Male and female Ksr2/ mice were hyperphagic
and rapidly gained body weight, in particular fat mass, when fed
ad libitum (Figures 5A–5D; Table S4). To assess the relative
contribution of hyperphagia to the weight gain of Ksr2/ mice,
we limited their food intake to the amount consumed by wild-
type mice (pair feeding [PF]). We found that despite being fed
the same amount of diet as Ksr2+/+ littermates from weaning,
Ksr2/ mice gained more weight. This excess weight was pre-
dominantly due to an increase in fat mass (Figures 5C and 5D;
Table S4). These data demonstrate that, in keeping with our
observations in humans with KSR2 mutations, both increased
energy intake and reduced energy expenditure contribute to
the obesity of Ksr2/ mice.
We sought to determine whether the energy expenditure
defect seen in Ksr2/ mice could be explained by impaired
mitochondrial FAO. As the inability tomaintain body temperature
when placed in a cold environment is a sensitive indicator of
impaired FAO in rodents (Guerra et al., 1998; Schuler et al.,
2005), we challenged additional cohorts of Ksr2/ mice by
housing them at 4C for up to 4 hr. Ad libitum fed male and
female Ksr2/ mice were cold tolerant at 6 weeks of age (Fig-
ures 5E, 5F, and S4) but became significantly cold intolerant by
10 weeks of age (Figures 5G, 5H, and S4).
Human KSR2 Mutations Impair Glucose Oxidation and
Fatty Acid Oxidation in Cells
Studies using mouse embryonic fibroblasts (MEFs) from Ksr2/
mice have suggested that the interaction between KSR2 and
AMPK may contribute to their abnormal energy homeostasis
and metabolism (Costanzo-Garvey et al., 2009). To investigate
the potential interaction between AMPK and human KSR2, we
performed immunoprecipitation of endogenously expressed
AMPK from HEK293 cells overexpressing Flag-tagged WT and
mutant KSR2. While all human KSR2 mutants bind AMPK, the
frameshift mutations and nonsense mutation that disrupt the
kinase domain and the missense mutant E667V, bound AMPK
with reduced affinity (Figure 6A). As the CA3 region and amino
acids located between the CA2 and CA3 regions contribute to
the ability of KSR2 to interact with the AMPKa subunit, we stud-
ied three additional mutations that lie within/close to this domain
(D323E, A373T, and R397H). One of these, A373T, exhibited
reduced AMPK binding (Figure 6A).
Activation of AMPK stimulates insulin-independent glucose
oxidation and inhibits the synthesis of long-chain fatty acids by
inhibiting acetyl-CoA carboxylase (ACC), thereby promoting
the beta-oxidation of long-chain fatty acids by enabling the
import of fatty acyl-CoA molecules into mitochondria. In previ-
ous studies, ectopic expression of Ksr2 in Ksr2/ MEFs
increased basal glucose uptake and palmitate-stimulated oxy-
gen consumption rate, a marker of FAO (Costanzo-Garvey
et al., 2009). We investigated the impact of human KSR2 muta-
tions on glucose oxidation using C2C12 cells overexpressing
WT and mutant forms of KSR2. Measurements of oxygen con-
sumption rate (OCR), as an indicator of oxidative phosphoryla-
tion, and extracellular acidification rate (ECAR) rate, as an index
of glycolysis (i.e., lactate production), were performed (Fig-
ure S5). We found that all mutations significantly reduced
glucose oxidation compared to WT KSR2 (Figure 6B).
To evaluate the role of KSR2 mutations in FAO, C2C12 cells
overexpressing KSR2mutants were differentiated intomyocytes
and OCR was measured prior to the addition of either 100 mMpalmitate complexed with BSA, or BSA alone (Figures 6C and
S5). We found that while cotransfection of WT KSR2 increased
palmitate-stimulated oxygen consumption, this effect was
reduced by all KSR2 mutants with the exception of I801L (Fig-
ure 6C). There is no obvious structural/molecular explanation
for why I801L affects glucose, but not fatty acid, oxidation.
Together, these data demonstrate that, when studied in cells,
KSR2 mutations are associated with disrupted fuel utilization.
Clinical reports suggested that some KSR2 mutation carriers
experienced marked weight loss in childhood when prescribed
the antidiabetic drug metformin (for severe insulin resistance).
Metformin (1,1-dimethylbiguanide) is themost widely prescribed
drug used in type 2 diabetes and can stimulate AMPK activation
(Hardie et al., 2012). We investigated the change in FAO seen
with the KSR2 mutants that previously had the greatest impact
upon FAO in response to 1 mMmetformin (Figure 6D). We found
that preincubation with metformin increased palmitate-stimu-
lated oxygen consumption in untransfected cells. Transfection
of WT KSR2 increased the basal level of FAO, which increased
further with metformin. The reduced basal level of FAO seen
with the KSR2 mutations was completely rescued in all cases
by the addition of metformin.
DISCUSSION
In this study, we linked the development of early-onset obesity
and severe insulin resistance in humans with rare variants in
KSR2, which affect its functional properties. When expressed
in cells, almost all of the KSR2 mutations impaired FAO and
glucose oxidation. In addition, several mutants disrupted Raf-
MEK-ERK signaling.
Most of the rare variants identified in severely obese individ-
uals affected highly conserved residues, were not found in
normal weight controls sequenced using the same methods,
and were associated with loss of function in a number of assays.
Therefore, we conclude that these KSR2 variants are likely to be
major drivers of the phenotype seen in the affected individuals.
Although rare loss-of-function variants in KSR2 are highly
enriched in cases versus controls, they do not consistently cose-
gregate with severe obesity and as such are likely to interact
with other genetic and/or environmental factors to modulate
the phenotype within and between families. Additional genetic
studies will be needed to determine whether these findings can
be replicated in comparable cohorts.
Some of the variants found in severely obese individuals were
also found in controls in this study; although notably some of
these controls were also overweight or obese. In addition,
some KSR2 variants have recently been reported in publicly
available exome data (Table S1). However, as BMI and additional
phenotypic information for individuals in these data sets are not
available, the precise contribution of these variants to obesity
remains to be established.
KSR2 Regulates Energy Intake and Expenditure in
Mouse and Man
Our physiological data demonstrate that KSR2 is a regulator of
food intake, basal metabolic rate, FAO, and glucose oxidation
in humans. While to date, other highly penetrant genetic formsCell 155, 765–777, November 7, 2013 ª2013 The Authors 771
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Figure 4. KSR2 Mutations Affect Energy Intake and Energy Expenditure in Humans
Data are presented for individuals carrying rare variants in KSR2 and obese controls in whom KSR2 variants were excluded. Values are mean ± SEM; *p < 0.05.
(A and B) Ad libitum energy intake at an 18MJ test meal presented after an overnight fast to children with KSR2mutations and normal weight children (A) and to
adults with KSR2 mutations compared to obese controls (B); intake is expressed as kilojoules per kilogram of lean mass.
(legend continued on next page)
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of obesity have predominantly been associated with hyperpha-
gia (Farooqi and O’Rahilly, 2006),KSR2mutations are in addition
associated with low BMR and reduced heart rate when tested
under the same experimental conditions as individuals with
other genetic forms of obesity (Farooqi et al., 2007; Greenfield
et al., 2009).
BMR accounts for approximately 70% of energy expenditure
in humans, with the remainder being attributable to voluntary
physical activity (20%) and nonexercise related activity thermo-
genesis (10%). Impaired sympathetic nervous system (SNS)
activation is a possible explanation for the low BMR observed,
but we consider this is unlikely given that RMSSD, LF power,
and HF power measurements of heart rate data were compara-
ble to measurements in obese controls. Furthermore, urinary
norepinephrine excretion was in the normal range in mutation
carriers, in contrast to measurements in individuals with other
genetic forms of obesity characterized by impaired SNS activa-
tion (Greenfield et al., 2009). However, these measurements
have their limitations, and further studies will be needed to mea-
sure sympathetic innervation and activation of adipose tissue, in
particular brown adipose tissue, which plays a key role in ther-
mogenesis and energy expenditure (Lowell and Spiegelman,
2000). Studies in additional KSR2 mutation carriers will be
needed to replicate these findings, establish whether loss-of-
function mutations impact on other components of energy
expenditure and to investigate whether a genotype/phenotype
correlation exists.
There is considerable overlap between the phenotypes we
observed in humans and those seen in Ksr2/ mice. Ksr2/
mice becomemarkedly obese after weaning while heterozygous
mice developed more modest, later-onset obesity (Revelli et al.,
2011). Our findings support a major role for hyperphagia as well
as reduced metabolic rate in the development of obesity associ-
ated with Ksr2 deficiency. Although Ksr2 is expressed in areas of
the hypothalamus known to be involved in mediating leptin’s
effects on food intake, such as the arcuate nucleus (Figure S4),
previous studies performed in Ksr2/mice did not convincingly
link leptin and melanocortin pathways to the obesity phenotype
(Revelli et al., 2011). We found that Ksr2/ mice tolerated cold
exposure at 6 weeks of age, when we saw little evidence for a
defect in energy expenditure; however, they were modestly
cold intolerant at 10 weeks of age, when weight gain occurred
despite pair-feeding. Previous studies have suggested that the
decreased energy expenditure seen in Ksr2/ mice is not
explained by decreased physical activity (Costanzo-Garvey
et al., 2009; data not shown).
KSR2Mutations Disrupt Multiple Signaling Pathways
While some of the rare KSR2 variants identified in this study may
affect the function of the protein through mechanisms that were
not tested here, we show that rare obesity-associated KSR2
mutations disrupt multiple molecular processes when studied
in cells. We found that all the frameshift mutants, the nonsense(C) Measured and predicted basal metabolic rate (BMR) adjusted for kg fat free
(D) Respiratory quotient as measured by indirect calorimetry.
(E) Heart rate (beats per minute) during sleep and in the awake state measured u
(F and G) Plasma insulin (pmol/l) and glucose (mmol/l) before and after a 75 g ormutant and several missense mutations reduced the ability of
KSR2 to facilitate signaling within the Raf-MEK-ERK pathway.
The assays used in these studies identified variants that were
clearly deficient in activity but may not have been able to differ-
entiate variants with mild loss of function.
Modulation of the intensity and duration of ERK signaling may
be a mechanism by which KSR2 mutations are associated with
metabolic disease. Diet-induced obesity in mice and humans
is associated with increased ERK1 activity in adipose tissue,
whereas Erk1/ mice appear resistant to diet-induced obesity
and remain insulin sensitive on a high-fat diet (Bost et al.,
2005). Leptin-deficient ob/ob mice crossed with Erk1/ mice
are partially protected against hyperglycemia and hepatic
steatosis despite developing severe obesity (Jager et al.,
2011), suggesting that ERK signaling modulates insulin sensi-
tivity independent of its potential direct effects on adipose tissue.
Ex vivo experiments suggest a role for KSR2 in liver, adipose
tissue, and skeletal muscle, tissues in which KSR2 mRNA has
been detected at low levels (Costanzo-Garvey et al., 2009). How-
ever, KSR2 protein is detectable by western blot only in the brain
(Figure S4). It therefore seems likely that most of the physiolog-
ical effects of KSR2 mutations may be mediated by central ner-
vous system pathways. Ras-Raf-MEK-ERK signaling is required
for normal brain development (Lanctot et al., 2013) and a
growing body of evidence suggests that neurotrophin-mediated
signaling through this pathway is involved in synaptic plasticity
(Canal et al., 2011; Shalin et al., 2006). Deletion and reactivation
of components of KSR2-mediated signaling in targeted neuronal
populationswill be needed to dissect the full functional repertoire
of centrally expressed KSR2.
We have shown that mutations associated with human obesity
and insulin resistance impair KSR2’s ability to stimulate fatty acid
and glucose oxidation, in transfected cells. The interaction of hu-
man KSR2with AMPK suggests a plausiblemechanism thatmay
contribute to some of the effects we observed in cells and in vivo,
although the precise pathways involved are likely to be highly
complex, tissue-specific, and altered by environmental factors
such as diet and exercise. In rodents, AMPK activation in hypo-
thalamic neurons can be modulated by peripheral nutritional sig-
nals such as the anorectic hormone leptin (Minokoshi et al.,
2004; Yang et al., 2011) and the orexigenic hormone ghrelin
(Kola et al., 2005). Direct injection of pharmacological activators
of AMPK into the hypothalamus promotes feeding (Andersson
et al., 2004), whereas disruption of AMPKa2 in neurons express-
ing anorectic POMC-derived peptides leads to obesity due to
reduced energy expenditure and increased food intake (Claret
et al., 2007).
Further studies will be needed to investigate the contribution
of downstream components of the KSR2-AMPK signaling com-
plex to energy homeostasis and glucose control. AMPK regu-
lates mTORC1 (mammalian target of rapamycin complex 1)
via direct phosphorylation of the tumor suppressor TSC2 and
the mTORC1 subunit Raptor, leading to inhibition of mTORC1mass in adults with KSR2 mutations.
sing a portable digital accelerometer.
al glucose load (given at time 0). See also Table S3.
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Figure 5. The Obesity of Ksr2/ Mice Is Due to Increased Energy Intake and Decreased Energy Expenditure and Is Associated with Cold
Intolerance
Body weight of Ksr2/ mice and WT littermates in response to ad libitum feeding and a pair-feeding paradigm.
(A) At weaning, male mice (12 Ksr2+/+ and 4 Ksr2/) were fed ad libitum. 9 Ksr2/mice were pair-fed (PF) the amount of diet consumed ad libitum by Ksr2+/+
mice. Although only 1 of 7 Ksr2/mice fed ad libitum survived to 15 weeks of age, all pair-fed mice survived to 18 weeks of age. Numbers above the Ksr2/ ad
libitum group data reflect the number of Ksr2/ ad libitummice alive at the time of the body weight measurement; all other mice survived to the end of the study.
(legend continued on next page)
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Figure 6. Human KSR2 Mutations Are Associated with Reduced Glucose and Fatty Acid Oxidation in Transfected Cells
(A) Lysates fromHEK293 cells transfected with the indicated KSR2 constructs were subjected to immunoprecipitation with Flag-agarose and immunoblottedwith
the indicated antibodies.
(B) Measurement of glucose oxidation in C2C12 cells using the Seahorse XF24 extracellular flux analyzer. C2C12 cells overexpressing wild-type and mutant
forms of KSR2 were stimulated with 2 mM FCCP and oxygen consumption rate (OCR) measured. Data were normalized to cell count by the sulphorhodamine B
(SRB) assay.
(C) Measurement of FAO in differentiated C2C12 cells using the Seahorse XF24 extracellular flux analyzer. C2C12 cells overexpressing wild-type and mutant
forms of KSR2 were stimulated with 100 mM palmitate and OCR measured. Values represent the means of three independent experiments. Error bars represent
SEM. The data are represented as % change from GFP-transfected control cells.
(D) Effect of metformin on FAO. C2C12 myocytes overexpressing wild-type and mutant forms of KSR2 were stimulated with 100 mM palmitate (Pal) and OCR
measured. Cells were preincubated with 1 mMmetformin (Met) for 1 hr prior to the start of the assay and metformin was present in the reaction buffer during the
assay. The data are represented as percentage (%) change from GFP transfected control cells. See also Figure S5.activity (Shaw, 2009). As hyperactivation of mTORC1 in POMC
neurons leads to hyperphagia and obesity in mice (Mori et al.,
2009), the increased phosphorylation of mTORC1 seen in the
hypothalamus of Ksr2/ animals (Revelli et al., 2011), may
contribute to their increased food intake. Depletion of KSR2 by
shRNA in MIN6 cells that express endogenous KSR2, is associ-
ated with a reduction in phosphorylated AMPK, ACC and Raptor
(Fernandez et al., 2012). However, these effects may be cell-line
dependent as we found that WT and mutant KSR2 had no effect(B) At weaning, female mice (10 Ksr2+/+ and 3 Ksr2/) were fed ad libitum. 6 Ks
Ksr2+/+ mice.
(C and D) Fat mass of pair-fed male and female mice.
(E) Rectal temperatures of 6 week-old male Ksr2+/+ (n = 9) and Ksr2/ (n = 10) m
(F) Rectal temperatures of 6 week-old female Ksr2+/+ (n = 10) and Ksr2/ (n = 9
(G) The same male mice presented in (E) were studied again at 10 weeks of age
(H) The same female mice presented in (F) were studied again at 10 weeks of age.
KO-PF and WT: ^ p < 0.01, ^^ p < 0.001. Error bars represent SEM.
See also Table S4 and Figure S4.on AMPK activation and TSC2 and Raptor phosphorylation in
HEK293, Cos7, or C2C12 cells in which endogenous KSR2
cannot be detected (Figure S5 and data not shown).
The anecdotal clinical observation that metformin treatment
leads to weight loss in some KSR2 mutation carriers needs to
be investigated further in a prospective, controlled clinical exper-
imental study with measurement of BMR, RQ, and insulin sensi-
tivity. Metformin improves insulin sensitivity, lowers blood
glucose and cholesterol, and reduces body weight in somer2/ mice were pair-fed (PF) to the amount of chow consumed ad libitum by
ice following cold exposure at 4C.
) mice following cold exposure at 4C.
.
Differences fromWT: *p < 0.05, **p < 0.01, ***p < 0.001; KO-ad lib different from
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individuals with type 2 diabetes, although the underlying mech-
anisms of action, which include modulating AMPK activation,
remain poorly understood (Viollet et al., 2012). We assessed
the ability ofWT andmutant forms of KSR2 to affect AMPKphos-
phorylation in the presence or absence of 1 mM metformin and
observed that metformin leads to phosphorylation of AMPK
Thr172 equally in cells transfected with WT and mutant forms
of KSR2 (Figure S5).
Further studies will be necessary to understand the extent to
which AMPK activation contributes to the full repertoire of met-
formin’s effects and its ability to ameliorate the effects of KSR2
mutations on substrate utilization. These observations and our
in vitro findings suggest that pharmacological approaches
based on the modulation of KSR2 activity could represent a
novel potential therapeutic strategy for the treatment of obesity
and type 2 diabetes.
EXPERIMENTAL PROCEDURES
Subjects and Ethical Permissions
DNA samples were obtained from individuals with severe early-onset obesity
from the GOOS cohort or from control individuals from the ELY study. Each
subject (or their parent for those under 16 years) provided written informed
consent; minors provided oral consent. Details of the phenotyping studies
are described in the Extended Experimental Procedures. Normal weight chil-
dren (n = 14) and obese adults (n = 26) were recruited for these studies by
advertisement in the local media. All participants were weight-stable non-
smokers and were not taking medications that could affect energy homeosta-
sis, gut absorption, or lipid/carbohydrate metabolism.
Immunoprecipitation and Immunoblotting
Cell lysates were immunoprecipitated using anti-Flag M2 affinity gel (Sigma)
and samples analyzed using SDS-PAGE and western blotting.
Immunofluorescence and Flow Cytometry
Fixed Cos7 cells on glass coverslips were immunostained and imaged using a
Zeiss LSM510 confocal microscope. Fixed HEK293 cells were immunostained
for flow cytometry before subsequent analysis on a BD FACS calibur flow
cytometer.
Structural Modeling
Modeling of KSR2 mutations onto the MEK1-KSR2 structure (PDB: 2Y4I)
(Brennan et al., 2011) was performed using COOT (Emsley and Cowtan, 2004).
Measurement of Glucose Oxidation and Fatty Acid Oxidation
Measurements were carried out on differentiated C2C12 myotubes using the
Seahorse XFe24 analyzer.
Mouse Husbandry
Ksr2 KO mice were maintained as described previously (Revelli et al., 2011).
Details of the mouse studies can be found in the Extended Experimental
Procedures.
Statistics
Genetic Studies
Fisher’s exact test was used to compare the number of rare (MAF < 0.5%)
variants between cases and controls. Permutation was used to calculate the
p value correcting for multiple testing over different MAF thresholds.
All Other Studies
Data are presented as mean ± SEM throughout. Comparisons between two
groups were analyzed by unpaired Student’s t test, and comparisons among
three groups were analyzed by one-way ANOVA with post hoc analysis per-
formed by the Bonferroni method, using PRISM 4.03 (GraphPad) software.
Values were considered statistically significant when p < 0.05.776 Cell 155, 765–777, November 7, 2013 ª2013 The AuthorsSUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and four tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2013.09.058.
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